Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Q3 2025 value amounting to $9.1 million.

  • Maravai Lifesciences Holdings' Share-based Compensation fell 3060.54% to $9.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.8 million, marking a year-over-year decrease of 2368.5%. This contributed to the annual value of $49.4 million for FY2024, which is 4286.75% up from last year.
  • According to the latest figures from Q3 2025, Maravai Lifesciences Holdings' Share-based Compensation is $9.1 million, which was down 3060.54% from $6.8 million recorded in Q2 2025.
  • In the past 5 years, Maravai Lifesciences Holdings' Share-based Compensation registered a high of $13.8 million during Q2 2024, and its lowest value of $2.2 million during Q4 2021.
  • Its 5-year average for Share-based Compensation is $7.3 million, with a median of $6.8 million in 2025.
  • Within the past 5 years, the most significant YoY rise in Maravai Lifesciences Holdings' Share-based Compensation was 34842.52% (2021), while the steepest drop was 8972.16% (2021).
  • Maravai Lifesciences Holdings' Share-based Compensation (Quarter) stood at $2.2 million in 2021, then soared by 168.83% to $6.0 million in 2022, then skyrocketed by 55.83% to $9.3 million in 2023, then grew by 12.88% to $10.5 million in 2024, then dropped by 14.12% to $9.1 million in 2025.
  • Its Share-based Compensation stands at $9.1 million for Q3 2025, versus $6.8 million for Q2 2025 and $10.4 million for Q1 2025.